Stance gene are closely linked to chloroquine resistance in PPARγ Agonist list Plasmodium falciparum. Nature 1990, 345:25558. 38. Duah NO, Matrevi SA, de Souza DK, Binnah DD, Tamakloe MM, Opoku VS, Onwona CO, Narh CA, Quashie NB, Abuaku B, Duplessis C, Kronmann KC, Koram KA: Enhanced pfmdr1 gene copy quantity plus the decline in pfcrt and pfmdr1 resistance allelles in Ghanaian Plasmodium falciparum isolates right after the transform of antimalarial drug remedy policy. Malar J 2013, 12:377. 39. Khalil IF, Alifrangis M, Tarimo DS, Staalso T, Satti GM, Theander TG, Ronn AM, Bygbjerg IC: The roles of your pfcrt 76 T and pfmdr1 86Y mutations, immunity and the initial level of parasitaemia, in predicting the outcome of chloroquine remedy in two locations with distinctive transmission intensities. Ann Trop Med Parasitol 2005, 99:44148. 40. MOH: Anti-Malaria Drug Policy for Ghana. Accra, Ghana: Ministry of Wellness; 2009. 41. Kwansa-Bentum B, Ayi I, Suzuki T, Otchere J, Kumagai T, Anyan WK, Asahi H, Akao N, Wilson MD, Boakye DA, Ohta N: Administrative practices of well being professionals and use of artesunate-amodiaquine by neighborhood members for treating uncomplicated malaria in southern Ghana: implications for artemisinin-based combination therapy deployment. Trop Med Int Health 2011, 16:1215224. 42. United Nation Basic Assembly: Implementation of General Assembly Resolution 66/289 on Consolidating Gains and Accelerating Efforts to Manage and Eliminate Malaria in Developing Nations, Especially in Africa, by 2015. 2012. United Nation document A/RES/66/289. 43. WHO: WHO Informal Consultation with Manufacturers of Artemisinin-Based Pharmaceutical Items in use for the Remedy of Malaria. Geneva: World Wellness Organization; 2007. 44. WHO: WHO briefing on Malaria Treatment Suggestions and artemisinin monotherapies. 2006. meeting_briefing19april.pdf. 45. Tucker M, Mutka T, Sparks K, Patel J, Kyle DE: Phenotype and genotype evaluation of in vitro-selected artemisinin-resistance progeny of plasmodium falciparum. Antimicrob Agent Chemother 2012, 56:30214. 46. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P, Mao S, Sopha C, Sam B, Anderson JM, Duong S, Chuor CM, Taylor WR, Suon S, Mercereau-Puijalon O, Fairhurst RM, Menard D: Novel pheno typic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia in vitro and ex-vivo drug-response studies. Lancet Infect Dis 2013, 13:1043049. 47. MOH: Guidelines for Case Management of Malaria in Ghana. Accra: Ministry of Health; 2009. 48. WHO: Survey of your high quality of selected antimalarial medicines circulating in six nations of sub-Saharan Africa. 2011. medicines/publications/WHO_QAMSA_report.pdf.49. Oduola AM, Milhous WK, Salako LA, Walker O, Desjardins RE: Reduced in-vitro susceptibility to mefloquine in West African isolates of Plasmodium falciparum. Lancet 1987, two:1304305. 50. Simon F, Le BJ, Gaudebout C, Girard PM: Lowered sensitivity of Plasmodium falciparum to mefloquine in West Africa. Lancet 1988, 1:46768. 51. TLR2 Antagonist Accession Crockett M, Kain KC: Tafenoquine: a promising new antimalarial agent. Professional Opin Investig Drugs 2007, 16:70515. 52. Pradines B, Mamfoumbi MM, Tall A, Sokhna C, Koeck JL, Fusai T, Mosnier J, Czarnecki E, Spiegel A, Trape JF, Kombila M, Rogier C: In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob Agents Chemother 2006, 50:322522.